iSpecimen (iSpecimen) ROCE %

: -101.26% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. iSpecimen's annualized ROCE % for the quarter that ended in Dec. 2023 was -101.26%.

iSpecimen ROCE % Historical Data

The historical data trend for iSpecimen's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iSpecimen Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-79.35

-37.37

-72.20

iSpecimen Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %															-36.26	-50.56	-84.89	-61.32	-101.26

iSpecimen ROCE % Calculation

iSpecimen's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-10.869	/	( ( (24.618 - 4.281)	+	(15.819 - 6.049) )	/ 2 )
	=	-10.869	/	( (20.337	+	9.77)	/ 2 )
	=	-10.869	/	15.0535
	=	-72.20 %

iSpecimen's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-11.416	/	( ( (16.295 - 3.517)	+	(15.819 - 6.049) )	/ 2 )
	=	-11.416	/	( ( 12.778	+	9.77 )	/ 2 )
	=	-11.416	/	11.274
	=	-101.26 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

iSpecimen (NAS:ISPC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

iSpecimen ROCE % Related Terms

Thank you for viewing the detailed overview of iSpecimen's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

iSpecimen (iSpecimen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » iSpecimen Inc (NAS:ISPC) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

450 Bedford Street, Lexington, MA, USA, 02420

Website

https://www.ispecimen.com

iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.

Executives

Benjamin Bielak	officer: Chief Information Officer	450 BEDFORD STREET, LEXINGTON MA 02420
Tracy Curley	officer: Chief Financial Officer	450 BEDFORD STREET, LEXINGTON MA 02420
Joseph J. Basile	director	450 BEDFORD STREET, LEXINGTON MA 02420
Andrew L. Ross	director, 10 percent owner	450 BEDFORD STREET, LEXINGTON MA 02420
Gullans Steven R. Ph.d.	director	C/O EXCEL VENTURE MANAGEMENT, LLC, 800 BOYLSTON ST., STE 2825, BOSTON MA 02199
John L Brooks	director	100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090
Obf Investments, Llc	10 percent owner	450 BEDFORD STREET, LEXINGTON MA 02420
Margaret H. Lawrence	director	450 BEDFORD STREET, LEXINGTON MA 02420
George H. Scholl	director	450 BEDFORD STREET, LEXINGTON MA 02420
Christopher Ianelli	director, officer: CEO, President	450 BEDFORD STREET, LEXINGTON MA 02420
Jill Mullan	director, officer: COO, Secretary, Treasurer	450 BEDFORD STREET, LEXINGTON MA 02420